Document is current
Any future updates will be listed below
-
Authors
Qu, Tingting https://orcid.org/0000-0003-4198-8900
Zhang, Shujing https://orcid.org/0000-0001-8956-1725
Zhong, Yichen
Meng, Yang
Guo, He
Joo, Seongjung
Enzinger, Peter C.
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
- License Information
-
More Information
Article History
Accepted: 13 September 2022
First Online: 15 October 2022
Declarations
:
: Yichen Zhong, Shujing Zhang, He Guo, and Seongjung Joo are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and report financial interests. Tingting Qu and Yang Meng are employees of Lumanity, who have received funding from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA for the conduct of this research. Peter C. Enzinger reports personal fees for consulting for ALX Oncology, Arcus Bioscience, Astellas, Astra-Zeneca, Blueprint Medicines, BMS, Celgene, Coherus, Daiichi-Sankyo, Five Prime, Ideaya, Istari, Legend, Lilly, Loxo, Merck, Novartis, Ono, Servier, Taiho, Takedo, Turning Point Therapeutics, Xencor, and Zymeworks.
: Not applicable.
: Not applicable.
: Not applicable.
: The excel model is not available.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: The corresponding author has full access to all the data in the study. Data sharing is available upon request.
: An E-poster of this article was presented at the European Society for Medical Oncology Congress 2021 during 16–21 September, 2021.
